Evogene Ltd (EVGN) Posts Earnings Results, Misses Estimates By $0.05 EPS

Evogene Ltd (NYSE:EVGN) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.13) by $0.05, Morningstar.com reports. The company had revenue of $1.18 million for the quarter. Evogene had a negative return on equity of 18.60% and a negative net margin of 235.47%.

Shares of Evogene (NYSE EVGN) traded up 0.21% during midday trading on Friday, reaching $4.76. The company’s stock had a trading volume of 3,250 shares. Evogene has a 12-month low of $4.57 and a 12-month high of $7.09. The company’s 50-day moving average price is $5.03 and its 200 day moving average price is $5.15. The company’s market capitalization is $122.55 million.

WARNING: “Evogene Ltd (EVGN) Posts Earnings Results, Misses Estimates By $0.05 EPS” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another site, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.com-unik.info/2017/08/12/evogene-ltd-evgn-posts-earnings-results-misses-estimates-by-0-05-eps.html.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. raised its position in Evogene by 53.4% in the first quarter. JPMorgan Chase & Co. now owns 245,425 shares of the biotechnology company’s stock worth $4,079,000 after buying an additional 85,425 shares during the period. UBS Group AG raised its position in Evogene by 10.1% in the first quarter. UBS Group AG now owns 1,052,537 shares of the biotechnology company’s stock worth $5,628,000 after buying an additional 96,527 shares during the period. Bank of America Corp DE raised its position in Evogene by 5.3% in the first quarter. Bank of America Corp DE now owns 841,552 shares of the biotechnology company’s stock worth $4,500,000 after buying an additional 42,532 shares during the period. Jane Street Group LLC raised its position in Evogene by 71.1% in the first quarter. Jane Street Group LLC now owns 50,129 shares of the biotechnology company’s stock worth $268,000 after buying an additional 20,837 shares during the period. Finally, Goldman Sachs Group Inc. raised its position in Evogene by 59.6% in the first quarter. Goldman Sachs Group Inc. now owns 606,962 shares of the biotechnology company’s stock worth $3,246,000 after buying an additional 226,778 shares during the period. 29.88% of the stock is owned by institutional investors.

About Evogene

Evogene Ltd. (Evogene) is a biotechnology company for the improvement of crop productivity. The Company is engaged in developing seed traits for improved yield and abiotic stress tolerance, seed traits for biotic stress resistance, herbicides and bio-stimulants. The Company operates a seed business under its subsidiary Evofuel Ltd.

Earnings History for Evogene (NYSE:EVGN)

What are top analysts saying about Evogene Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Evogene Ltd and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit